Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ELEDON PHARMACEUTICALS, INC.

(ELDN)
  Report
Delayed Nasdaq  -  03:50:39 2023-01-27 pm EST
3.290 USD   -0.90%
01/09Eledon Pharmaceuticals, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
01/09Eledon Pharmaceuticals Provides Business and Pipeline Updates
GL
01/09EGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Preclinical Xenotransplantation Studies
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

11/03/2022 | 03:07pm EST

Management to host conference call and webcast at 4:30 pm ET

IRVINE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), today announced that it plans to release financial results for the third quarter ended September 30, 2022 on Monday, November 14, after the close of trading. Eledon’s management team will host a conference call and webcast beginning at 4:30 p.m. ET.

Conference Call and Webcast Details:

Monday, November 14, 2022 at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time
Toll Free: 877-300-8521
International: 412-317-6026
Conference ID: 10171988
Webcast: https://ir.eledon.com/events-and-presentations/events

After the live webcast, the event will be archived on Eledon’s website for one year.

About Eledon Pharmaceuticals and tegoprubart (formerly AT-1501)

Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525 2047
stephen@gilmartinir.com


All news about ELEDON PHARMACEUTICALS, INC.
01/09Eledon Pharmaceuticals, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits..
AQ
01/09Eledon Pharmaceuticals Provides Business and Pipeline Updates
GL
01/09EGenesis and Eledon Pharmaceuticals Announce Collaboration for Use of Tegoprubart in Pr..
AQ
01/09Eledon Pharmaceuticals Provides Business and Pipeline Updates
AQ
01/09Egenesis and Eledon Pharmaceuticals Announces Collaboration for Use of Tegoprubart in P..
CI
2022C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox..
GL
2022C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox..
AQ
2022ELEDON PHARMACEUTICALS, INC. Management's Discussion and Analysis of Financial Conditi..
AQ
2022Eledon Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Mo..
CI
2022Transcript : Eledon Pharmaceuticals, Inc., Q3 2022 Earnings Call, Nov 14, 202..
CI
More news
Analyst Recommendations on ELEDON PHARMACEUTICALS, INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -40,9 M - -
Net Debt 2022 - - -
P/E ratio 2022 -1,26x
Yield 2022 -
Capitalization 45,3 M 45,3 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 1,81x
Nbr of Employees 12
Free-Float 90,2%
Chart ELEDON PHARMACEUTICALS, INC.
Duration : Period :
Eledon Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 3,29 $
Average target price 19,40 $
Spread / Average Target 490%
EPS Revisions
Managers and Directors
David-Alexandre C. Gros Chief Executive Officer & Director
Steven N. Perrin President, Director & Chief Scientific Officer
Paul Little Chief Financial & Accounting Officer
Keith A. Katkin Chairman
Jeffrey D. Bornstein Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
ELEDON PHARMACEUTICALS, INC.44.30%45
VERTEX PHARMACEUTICALS11.16%82 513
REGENERON PHARMACEUTICALS, INC.2.88%79 336
WUXI APPTEC CO., LTD.20.37%42 407
BIONTECH SE-4.37%34 912
BEIGENE, LTD.18.12%27 008